Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

A meta-analysis for response to treatment was undertaken using individual data of multidrug-resistant tuberculosis (MDR-TB) (resistance to isoniazid and rifampicin) patients from 26 centres. The analysis assessed the impact of additional resistance to fluoroquinolones and/or second-line injectable d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The European respiratory journal Ročník 42; číslo 1; s. 156
Hlavní autoři: Falzon, Dennis, Gandhi, Neel, Migliori, Giovanni B, Sotgiu, Giovanni, Cox, Helen S, Holtz, Timothy H, Hollm-Delgado, Maria-Graciela, Keshavjee, Salmaan, DeRiemer, Kathryn, Centis, Rosella, D'Ambrosio, Lia, Lange, Christoph G, Bauer, Melissa, Menzies, Dick
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.07.2013
Témata:
Anti-Bacterial Agents - administration & dosage
Antitubercular Agents - administration & dosage
Data Collection
Drug Resistance, Bacterial
Fluoroquinolones - pharmacology
Humans
Mycobacterium tuberculosis - metabolism
Observational Studies as Topic
Treatment Failure
Treatment Outcome
Tuberculosis, Multidrug-Resistant - drug therapy
ISSN:1399-3003, 1399-3003
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:A meta-analysis for response to treatment was undertaken using individual data of multidrug-resistant tuberculosis (MDR-TB) (resistance to isoniazid and rifampicin) patients from 26 centres. The analysis assessed the impact of additional resistance to fluoroquinolones and/or second-line injectable drugs on treatment outcome. Compared with treatment failure, relapse and death, treatment success was higher in MDR-TB patients infected with strains without additional resistance (n=4763; 64%, 95% CI 57-72%) or with resistance to second-line injectable drugs only (n=1130; 56%, 95% CI 45-66%), than in those having resistance to fluoroquinolones alone (n=426; 48%, 95% CI 36-60%) or to fluoroquinolones plus second-line injectable drugs (extensively drug resistant (XDR)-TB) (n=405; 40%, 95% CI 27-53%). In XDR-TB patients, treatment success was highest if at least six drugs were used in the intensive phase (adjusted OR 4.9, 95% CI 1.4-16.6; reference fewer than three drugs) and four in the continuation phase (OR 6.1, 95% CI 1.4-26.3). The odds of success in XDR-TB patients was maximised when the intensive phase reached 6.6-9.0 months duration and the total duration of treatment 20.1-25.0 months. In XDR-TB patients, regimens containing more drugs than those recommended in MDR-TB but given for a similar duration were associated with the highest odds of success. All data were from observational studies and methodologies varied between centres, therefore, the bias may be substantial. Better quality evidence is needed to optimise regimens.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1399-3003
1399-3003
DOI:10.1183/09031936.00134712